arrow
C

Celeste Porsbjerg

University of Copenhagen
H指数:47
被引数:8,682

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study

易得生物制剂与重症哮喘缓解及其他临床结局的关联:一项全球真实世界研究

2026-08-060
OA
Five-year inhaled, systemic and total corticosteroid exposure reduction during anti-Interleukin-5/Rα treatment for severe asthma

重度哮喘患者接受抗白介素-5/白介素-5受体α治疗期间,五年吸入性、系统性及总皮质类固醇暴露量的减少

2026-04-030
OAAI
Long-term efficacy but rare sustained remission: individual-level 5-year stability in anti-IL5/Rα biologic therapy response for severe asthma
2026-03-010
PRE
Mortality in severe asthma: results from the NORDSTAR cohort

重症哮喘的死亡率——来自NORDSTAR队列的研究结果

2026-03-012
PRE
Identifying an At-Risk Asthma Phenotype: Allergy and Recurrent Infections Predict Severe Disease

识别高风险哮喘表型:过敏和反复感染预示严重疾病

2026-02-080
OAAI
Clustering of the Bronchial Epithelial Immune Response to Viral Stimulation in Patients With Asthma Identifies Clinically Recognisable Epithelial Exacerbation Response Profiles

哮喘患者支气管上皮对病毒刺激的免疫反应聚类可识别出临床上可识别的上皮加重反应谱。

2025-12-100
PRE
Tezepelumab in real-life practice: Characteristics of patients commenced and efficacy in a nationwide, Danish cohort of patients with severe asthma.

泽替帕玛单抗在真实世界实践中的使用:丹麦全国范围内重症哮喘患者队列中开始使用该药物的患者特征及其疗效。

2025-09-110
PRE
Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach

对重度哮喘患者T2炎症程度梯度下生物制剂应答的研究:一种数据驱动的生物标志物聚类方法

2025-09-020
OAAI
Biologic Prescription Patterns and Biomarker Determinants of First-Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic Dermatitis

丹麦严重哮喘合并特应性皮炎成人患者中,第一线度普利珠单抗的生物制剂处方模式及生物标志物决定因素

2025-07-150
OAAI
Prediction Pathway for Severe Asthma Exacerbations

严重哮喘急性发作的预测通路

CHEST
IF8.6
2025-05-190
OA